A global private equity and venture capital firm with offices in the UK and the US has been investing in life sciences and healthcare for over 30 years and manages approximately $3.7 billion in AUM across several funds. The firm focuses on four key areas: therapeutics, dementia, healthcare growth, and medtech. For therapeutics, the firm is stage-agnostic and invests across all stages, from seed to crossover rounds approaching IPO. It also engages in company creation and building, allowing it to invest at very early stages in those cases. The average check size ranges from $5 million to $25 million, with the possibility of follow-on investments. While the firm prefers to lead, it is open to co-investing and will consider taking board positions on a case-by-case basis. As a transatlantic firm, the firm considers opportunities globally, with a focus on Europe and the US.
The firm invests in therapeutics, healthcare, and medtech. The therapeutics team is agnostic to both modalities and indications, considering a wide range of opportunities within the traditional therapeutics space. The firm is also stage-agnostic, investing at any stage from pre-clinical to late phases. In addition, the firm manages a separate fund which focuses exclusively on companies developing or enabling novel therapeutics for dementia.
The firm does not have specific requirements for the company or management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment